Topical tazarotene vs. coal tar in stable plaque psoriasis.
BACKGROUND
The efficacy of topical tazarotene has not previously been compared with the conventional topical treatment of crude coal tar (CCT) in stable plaque psoriasis.


OBJECTIVE
To assess the comparative efficacy and tolerability of topical tazarotene 0.1% gel and CCT 5% ointment in stable plaque psoriasis.


METHODS
In this nonblinded side-to-side comparison study, patients with chronic stable plaque psoriasis, who had bilaterally symmetrical plaques on the limbs, applied 0.1% tazarotene gel on the right side and 5% CCT ointment on the left side once daily for 12 weeks followed by an 8-week treatment-free follow up period. Severity of psoriatic lesions and response to treatment was evaluated by scoring erythema, scaling and induration (ESI).


RESULTS
Of 30 patients recruited, 27 could be assessed. In the per-protocol analysis, the mean percentage reduction in ESI score at the end of the treatment period was 74.15% +/- 9.43 and 77.37% +/- 10.93 with tazarotene and CCT, respectively (P > 0.05). A reduction in ESI score of > 75% was seen in 11 (40.74%) and 16 (59.26%) patients with tazarotene and CCT, respectively, at the end of 12 weeks. Side-effects were seen in 48.14% of patients treated with tazarotene, but in no patient treated with CCT.


CONCLUSIONS
Tazarotene 0.1% gel has comparable clinical efficacy to CCT 5% ointment. CCT ointment remains a cost-effective therapy for plaque psoriasis.
Kumar
U
U
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Kaur
I
I
Dogra
S
S
De
D
D
Kumar
B
B
D000287:Administration, Topical; D000328:Adult; D003033:Coal Tar / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D009539:Nicotinic Acids / Q000008:administration & dosage*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult; D012176:Retinoids
D003033:Coal Tar; D003879:Dermatologic Agents; D007641:Keratolytic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids